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A B S T R A C T
Articular cartilage is frequently injured by trauma or osteoarthritis, with limited and inadequate treatment
options. We investigated a new strategy based on hydrogel-mediated delivery of a locked nucleic acid microRNA
inhibitor targeting miR-221 (antimiR-221) to guide in situ cartilage repair by endogenous cells.
First, we showed that transfection of antimiR-221 into human bone marrow-derived mesenchymal stromal
cells (hMSCs) blocked miR-221 expression and enhanced chondrogenesis in vitro. Next, we loaded a fibrin/
hyaluronan (FB/HA) hydrogel with antimiR-221 in combination or not with lipofectamine carrier. FB/HA
strongly retained functional antimiR-221 over 14 days of in vitro culture, and provided a supportive environment
for cell transfection, as validated by flow cytometry and qRT-PCR analysis. Seeding of hMSCs on the surface of
antimiR-221 loaded FB/HA led to invasion of the hydrogel and miR-221 knockdown in situ within 7 days.
Overall, the use of lipofectamine enhanced the potency of the system, with increased antimiR-221 retention and
miR-221 silencing in infiltrating cells. Finally, FB/HA hydrogels were used to fill defects in osteochondral
biopsies that were implanted subcutaneously in mice. FB/HA loaded with antimiR-221/lipofectamine sig-
nificantly enhanced cartilage repair by endogenous cells, demonstrating the feasibility of our approach and the
need to achieve highly effective in situ transfection.
Our study provides new evidence on the treatment of focal cartilage injuries using controlled biomaterial-
mediated delivery of antimicroRNA for in situ guided regeneration.
1. Introduction
The repair of articular cartilage damaged by trauma or osteoar-
thritis represents an unmet clinical need. When conservative manage-
ment is no longer possible, surgical interventions including micro-
fracture and osteochondral grafting are considered. Unfortunately,
these procedures do not lead to the production of long-lasting func-
tional hyaline cartilage. Encouragingly, cell-based therapies have
emerged as a new opportunity. Autologous chondrocyte implantation
(ACI) was shown to be superior to microfracture for treating cartilage
defects after a 5-year follow-up [1]. Transplantation of human me-
senchymal stromal cells (hMSCs) is at an earlier stage, but phase I/II
clinical trials have proved its safety and therapeutic potential [2–4].
Nevertheless, the implementation of cell therapy into clinical practice is
facing several hurdles, due to the extensive cost and time required for in
vitro cell manipulation, as well as regulatory issues related to safety and
quality control [5].
The formation of cartilaginous tissue following microfracture sur-
gery indicates that cartilage repair can be achieved by directly stimu-
lating joint-resident progenitor cells in situ [6]. Perforation of the sub-
chondral bone induces a healing response where bone marrow-resident
cells access the lesion and trigger repair. Previous studies confirmed
that progenitor cells in the bone marrow and in the synovium can mi-
grate towards the sites of cartilage damage and initiate the repair of
partial or full-thickness cartilage defects [7,8]. Unfortunately, the re-
pair tissue produced after microfracture is mainly of fibrocartilaginous
nature and was shown to undergo deterioration within 2 years of sur-
gery [9]. To address these concerns, the combination of microfracture
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with the implantation of a scaffold or a hydrogel was proposed, as in the
case of the autologous matrix-induced chondrogenesis approach using a
collagen membrane [10], or the BST-CarGel approach using a chitosan
hydrogel and autologous blood [11]. Besides providing structural sup-
port and a scaffold for progenitor cells to colonize the defect, this could
enable the delivery of bioactive molecules to improve endogenous re-
pair. In this context, the development of matrices loaded with gene
constructs is an attractive option to deliver therapeutics and orient the
fate of progenitor cells in situ (e.g. [12–15]). Such an approach could
circumvent the issues of cell therapy and have an easier path to the
clinic.
In recent years, the characterization of chondro-regulatory
microRNAs (miRNAs) has reshaped our understanding of the control of
cartilage homeostasis. miRNAs are small non-coding RNAs that regulate
gene expression by base-pairing with complementary mRNAs and in-
hibiting their translation. miRNAs are major regulators of osteo-chon-
drogenic differentiation of progenitor cells and represent highly at-
tractive targets for stimulating osteochondral repair [16–18].
Implantation of microRNA-transfected cells in combination with sup-
portive scaffolds was previously shown to improve osteochondral repair
in vivo (reviewed in [15]). Nevertheless, only few initial studies have
investigated the use of miRNA-loaded collagen-based scaffolds to sti-
mulate bone repair by endogenous cells [12,19]. In the field of cartilage
repair, the possibility to employ miRNA-loaded matrices to stimulate
endogenous healing is still uncharted territory.
We previously characterized miR-221 as novel anti-chondrogenic
miRNA, and found that silencing miR-221 in cultured bone marrow-
derived hMSCs induced chondrogenesis [20,21]. Implantation of miR-
221 depleted hMSCs in a cartilage defect model significantly enhanced
cartilage repair in vivo [21]. Thus, we hypothesized that silencing miR-
221 in endogenous progenitor cells could stimulate cartilage repair.
With the aim to develop such a strategy, we here loaded a fibrin/
hyaluronan (FB/HA) hydrogel with a locked nucleic acid (LNA)-
microRNA inhibitor against miR-221 (antimiR-221), with or without
lipofectamine carrier. We performed in vitro studies to investigate the
ability of the constructs to retain antimiR-221 and deliver it to bone
marrow-derived stromal cells infiltrating the hydrogels. We then
exploited an in vivo osteochondral defect model to test the ability of
antimiR-221 loaded FB/HA to stimulate endogenous cartilage repair.
2. Materials and methods
2.1. Hydrogel preparation and loading with LNA-antimiR oligonucleotides
A FB/HA conjugate hydrogel (RegenoGel™) [22] was kindly pro-
vided by ProCore Biomed Ltd. (Nes Ziona, IL). The conjugate is com-
posed of FB and HA in a 3.2:1 ratio, with a final concentration of
6.25mg/mL FB and 1.95mg/mL HA. In comparison to hydrogels pre-
pared from FB alone or from a mixture of FB and HA, FB/HA conjugate
hydrogels show enhanced stability and mechanical properties, with
reduced loss of water and shrinkage overtime, as well as more pro-
nounced viscoelastic properties [22].
FB/HA hydrogel constructs for in vitro cultures were prepared by
mixing 150 μL of FB/HA conjugate with 10 μL of 50 U/mL thrombin
(Sigma-Aldrich). When required, hMSCs were resuspended in the hy-
drogels prior to the addition of thrombin at a low concentration
(3.5×106 cells/mL, in analogy to previous reports [22]). The hydro-
gels were allowed to polymerize at 37 °C for 30min in 96-well culture
plates, then removed from the plates and used for the experiments.
To prepare antimiR-loaded hydrogels, FB/HA was loaded with the
indicated concentrations of miRCURY LNA miRNA Power Inhibitor “in
vivo ready” against miR-221-3p (antimiR-221; QIAGEN), 6-FAM 5′-la-
belled miRCURY LNA miRNA Power Inhibitor against miR-221-3p
(fluorescently labelled antimiR-221; QIAGEN) or miRCURY LNA
miRNA Power Inhibitor “in vivo ready” mismatch scramble control
(antimiR-Scr; QIAGEN), prior to polymerization. These chemically-
modified oligonucleotides contain LNA bases and a phosphorothioate
backbone that can stimulate the process of gymnotic delivery [23]. “In
vivo ready” refers to the purification of the inhibitors with standards
suitable for in vivo delivery, i.e. HPLC and Na+ salt exchange. For
carrier-assisted transfection, Lipofectamine® RNAiMAX Reagent (Ther-
moFisher Scientific) was used as delivering agent and pre-incubated
with antimiR-221 or antimiR-Scr and Opti-MEM Reduced Serum
Medium (ThermoFisher Scientific) for 20min at room temperature,
following the manufacturer's instructions.
Collagen I hydrogels were prepared by mixing on ice 1.2mg/mL
collagen I (from rat tail; ThermoFisher Scientific) with 10× phosphate
buffered saline (PBS), distilled water and 1 N NaOH. Similarly to FB/
HA, the hydrogels were loaded with hMSCs and/or antimiR-221 and
polymerized at 37 °C in culture plates until firm constructs were formed
(30–40min).
2.2. Analysis of antimiR-221 retention by FB/HA hydrogels
FB/HA hydrogels were loaded with 4 μM fluorescently labelled
antimiR-221 with or without Lipofectamine® RNAiMAX Reagent.
100 μL hydrogel constructs were polymerized in 96-well plates, as de-
scribed. 200 μL of PBS 1× were added on top of the hydrogels and the
plates were incubated at 37 °C in a humidified atmosphere of 5% CO2,
up to 14 days. At every indicated time-point, the releasates were col-
lected and replaced with fresh PBS. At the end of the experiment, the
hydrogels were enzymatically digested with 2mg/mL collagenase B
(Sigma-Aldrich) in PBS at 37 °C for 90min to retrieve the fraction of
antimiR-221 that was still retained by the hydrogels. The antimiR-221
content of the samples was quantified by measuring the fluorescent
signal at λ=518 nm with a Spectramax microplate reader (Molecular
Devices, CA, USA). The cumulative release of antimiR-221 from the
hydrogels was determined following interpolation with a standard
curve. The experiments were performed with triplicate samples.
2.3. hMSC isolation and culture
hMSCs were isolated from the femoral biopsies of donors (age
50–78 years) undergoing total hip replacement, after signed informed
consent and approval of the local ethical committees (Erasmus MC
METC-2015-644; Albert Schweizer Hospital 2011.07). Cells were
seeded at a density of 5× 104 nucleated cells/cm2 in expansion
medium (10% Fetal Calf Serum α-MEM (ThermoFisher Scientific)
supplemented with 1 ng/mL FGF2 (AbD Serotec), 25 μg/mL ascorbic
acid-2-phosphate (Sigma-Aldrich), 1.5 μg/mL fungizone, and 50 μg/mL
gentamicin), at 37 °C in a humidified atmosphere of 5% CO2. After 24 h,
non-adherent cells were washed off. At subconfluence, adherent hMSCs
were trypsinized and replated at a density of 2.3× 103 cells/cm2. The
culture medium was refreshed twice a week and expanded cells at
passage 2 to 4 were used for the experiments.
To confirm the functionality of antimiR-221, hMSCs cultured in
monolayer were transfected with 5–50 nM antimiR-221, with or
without lipofectamine. The transfected cells were cultured in 10% Fetal
Calf Serum α-MEM (ThermoFisher Scientific) supplemented with
25 μg/mL ascorbic acid-2-phosphate (Sigma-Aldrich), 1.5 μg/mL fun-
gizone, and 50 μg/mL gentamicin for 3 days at 37 °C in a humidified
atmosphere of 5% CO2, prior to RNA isolation. In order to test antimiR-
221 stability over time, 250 nM antimiR-221 with or without lipo-
fectamine in PBS was pre-incubated at 37 °C for 14 days, prior to hMSC
transfection. The transfected cells were cultured for 3 days at 37 °C in a
humidified atmosphere of 5% CO2, prior to RNA isolation.
To assess the effect of antimiR-221 on chondrogenesis, hMSCs cul-
tured in monolayer were transfected twice with 25 nM antimiR-221, as
previously described [21]. hMSCs were then seeded in 15mL-poly-
propylene conical tube and centrifuged to form 3D pellets (2× 105
cells/pellet). The pellets were cultured in DMEM-high-glucose Glu-
taMAX+ (GIBCO) supplemented with 1% ITS+, 40 μg/mL L-proline
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(Sigma-Aldrich), 1 mM sodium pyruvate (GIBCO), 100 nM dex-
amethasone (Sigma-Aldrich), 1.5 μg/mL fungizone, 50 μg/mL genta-
micin and 10 ng/mL Transforming Growth Factor β1 (TGF-β1; R&D
Systems) for 28 days. The culture medium was renewed twice a week.
To confirm the ability of hMSCs to undergo chondrogenesis in FB/
HA, hydrogels were loaded with hMSCs and polymerized as described
in the previous paragraph. The hydrogels were cultured in chondro-
permissive medium (DMEM-high-glucose GlutaMAX+ (GIBCO), 1%
ITS+, 40 μg/mL L-proline (Sigma-Aldrich), 1 mM sodium pyruvate
(GIBCO), 100 nM dexamethasone (Sigma-Aldrich), 1.5 μg/mL fungi-
zone, and 50 μg/mL gentamicin) containing 0.0875 IU/mL aprotinin
(Sigma-Aldrich) and supplemented or not with 10 ng/mL Transforming
Growth Factor β1 (TGF-β1; R&D Systems) to stimulate chondrogenesis,
for 28 days. The culture medium was renewed twice a week.
2.4. Transfection of hMSCs in antimiR-loaded FB/HA hydrogels
To evaluate the ability of FB/HA to support cell transfection, hMSCs
were resuspended in FB/HA loaded with antimiR-221 with lipofecta-
mine. Hydrogel constructs were formed in duplicates or triplicates as
previously described and cultured in chondro-permissive medium
containing 0.0875 IU/mL aprotinin for 7 days, with a medium renewal
twice per week. For the assessment of transfection efficiency, the hy-
drogels were enzymatically digested with 2mg/mL collagenase B
(Sigma-Aldrich) in PBS at 37 °C for 90min. Next, α-MEM medium
supplemented with 10% FCS was added and samples were centrifuged
for 8min at 400 g. Cell pellets were resuspended in PBS and the cell
suspensions were filtered with 70 μm strainers. Flow cytometry analysis
was performed to quantify the % of hMSCs transfected with fluores-
cently labelled antimiR-221 using BD FACSCanto II (BD Biosciences,
CA, USA). Data were analyzed using BD FACSDiva software (BD
Biosciences, CA, USA). For the assessment of miR-221 silencing, the
hydrogels were manually homogenized and subjected to RNA isolation.
To assess the possibility to silence cells that invade a hydrogel,
200 μL hydrogel FB/HA constructs loaded with antimiR with or without
lipofectamine were polymerized in 48-well plates in duplicates or tri-
plicates as described above. 5×105 hMSCs were seeded on top of the
hydrogels in 200 μL of 10% Fetal Calf Serum α-MEM (ThermoFisher
Scientific) supplemented with 1 ng/mL FGF2 (Bio-Rad, UK), 25 μg/mL
ascorbic acid-2-phosphate (Sigma-Aldrich), 1.5 μg/mL fungizone, and
50 μg/mL gentamicin. Cells were allowed to adhere for 1 h, before
adding 300 μL of medium. The hydrogels were cultured for 7 days with
a medium renewal on day 3, prior to RNA isolation to assess miR-221
silencing. In order to test antimiR-221 stability in FB/HA, hydrogels
loaded with antimiR-221 with or without lipofectamine were pre-in-
cubated at 37 °C for 14 days, prior to hMSC seeding. Following cell
seeding, the hydrogels were further cultured for 7 days with a medium
renewal on day 3, prior to RNA isolation.
2.5. Analysis of hMSC viability in FB/HA hydrogels
To measure hMSC viability in FB/HA hydrogels, AlamarBlue Cell
Viability assay (ThermoFisher Scientific) was performed at day 7 and
14 of culture. Briefly, AlamarBlue was added in the culture medium at a
volume ratio of 1:10 and incubated for 8 h at 37 °C. Next, light absor-
bance at 570 nm and 600 nm was measured using a Spectramax mi-
croplate reader (Molecular Devices, CA, USA), according to the manu-
facturer's instructions. Results were normalized to medium control and
expressed as % of AlamarBlue reduction.
2.6. RNA isolation and qRT-PCR
FB/HA hydrogels and hMSC pellets were manually homogenized in
700 μL of QIAzol Lysis Reagent (QIAGEN) and total RNA including
miRNAs was purified using the miRNeasy Micro Kit (QIAGEN), ac-
cording to the manufacturer's instructions. RNA concentration and
quality was determined using a NanoDrop ND1000 UV-VIS spectro-
photometer (ThermoFisher Scientific). cDNA was synthesized from
total RNA in a 20 μL reaction volume using the TaqMan MicroRNA
Reverse Transcription kit (ThermoFisher Scientific) for the analysis of
microRNAs, or the RevertAid First Strand cDNA synthesis kit (MBI
Fermentas) for the analysis of mRNAs.
Quantification of miR-221-3p was performed with TaqMan
MicroRNA Assays (ThermoFisher Scientific), using U6 snRNA for nor-
malization. For the analysis of expression of genes indicative for
chondrogenic differentiation, collagen II, aggrecan and collagen X were
used, with hypoxanthine-guanine phosphoribosyltransferase (HPRT)
gene for normalization of mRNA abundances. Polymerase chain reac-
tions were performed using the TaqMan Universal PCR MasterMix
(ThermoFisher Scientific) and the CFX96TM PCR detection system (Bio-
Rad). Relative gene expression was calculated using the comparative 2-
ΔCt method.
2.7. RNA-sequencing and bioinformatic analysis
To assess the effect of miR-221 silencing on gene expression, hMSCs
cultured in monolayer were transfected with 25 nM antimiR-221 or
antimiR-Scr in combination with lipofectamine (n=3 hMSC donors).
24 h post-transfection, total RNA including miRNAs was purified as
described in the previous paragraph. After confirming effective miR-
221 silencing by qRT-PCR, the TruSeq RNA Library prep kit V2
(Illumina) was used to capture poly(A) RNA from 400 ng total RNA.
Subsequently cDNA was produced and dual indexed adapters were li-
gated. The material was amplified by PCR (13 cycles), product size was
checked on Labchip GX and product concentration was measured with
picogreen. Paired-end sequencing of 2× 150 bp was performed using
the Illumina Novaseq platform to obtain 6GB per sample. Reads were
extracted from the raw sequencing data using CASAVA 1.8.2 (Illumina)
and aligned to the human reference genome (UCSC's hg19) using the
STAR (2.5.0c) splice aware aligner with the gencode v19 transcriptome
annotations as additional template. The BAM files were processed using
the picard software suite (v1.90) and the Genome Analysis ToolKit
(GATK, v3.5). QC metrics were collected at various steps using picard
and evaluated along with coverage metrics using GATK. Read counts
per exon/gene were then determined by the featureCounts function of
the subread package (v1.4.6-p1) using the gencode v19 annotation as
markers. The resulting reads were processed using R software (https://
cran.r-project.org/) and the DESEQ2 package for NGS analysis. A
threshold of 5000 reads per gene was set to filter out low variance
genes. Finally, a differential expression (DE) analysis was performed in
order to identify the genes that were significantly modulated by
antimiR-221 transfection (adjusted p-value≤ .05).
To evaluate whether the genes significantly upregulated by antimiR-
221 transfection included predicted/validated targets of miR-221, a
cross-reference analysis with microRNA target databases was per-
formed (miRwalk: http://zmf.umm.uni-heidelberg.de/apps/zmf/
mirwalk2/; miRtarBase: http://mirtarbase.mbc.nctu.edu.tw/php/
index.php; starBase: http://starbase.sysu.edu.cn/; miRDB: http://
mirdb.org/; TargetScan: http://www.targetscan.org/vert_72/). Only
genes that were predicted as putative targets of miR-221 by at least
three databases were considered.
To identify whether the observed changes in gene expression could
be attributed to the modulation of specific upstream regulators, an
Ingenuity Pathway Analysis (IPA) (QIAGEN) was performed using the
genes significantly modulated by antimiR-221 treatment as input. An
IPA z-score≥ 2.0 and ≤−2.0 was set for the prediction of activated
and inhibited upstream regulators, respectively.
2.8. In vivo osteochondral defect model for endogenous cartilage repair with
antimiR-loaded FB/HA hydrogels
An osteochondral biopsy model previously established by our group
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[24,25] was adapted for the assessment of endogenous cartilage repair
in vivo. Briefly, osteochondral biopsies that were 8mm in diameter and
4mm in length were produced with a drill from the metacarpal bones of
fresh metacarpal-phalangeal joints of 3 to 8month-old calves obtained
from the slaughterhouse. Using a 4mm-diameter dermal biopsy punch
(Stiefel Laboratories, Germany) and a scalpel, osteochondral defects
were created by removing the cartilage and part of the subchondral
bone. The specimens were incubated overnight in α-MEM medium
supplemented with 10% FCS, 1.5 μg/mL fungizone and 50 μg/mL gen-
tamicin to verify sterility. Next, the osteochondral defects were filled
with 30 μL FB/HA loaded with 0.04 μg antimiR-221 with or without
lipofectamine or FB/HA loaded with 0.4 μg antimiR-221 without lipo-
fectamine. Defects filled with FB/HA only (control) or not filled with
hydrogel (empty) were included. The specimens were incubated at
37 °C for 30min, allowing in situ polymerization of the hydrogels.
The osteochondral biopsies were covered with Neuro-Patch mem-
brane (Braun, Germany) to prevent ingrowth of host cell/tissue and
implanted subcutaneously on the back of 10 to 14 week old female
NMRI nu/nu mouse (Taconic Biosciences) under isoflurane anesthesia.
Before surgery and 6 h after surgery, mice received 0.05mg/Kg body-
weight of Temgesic (Reckitt Benckiser). During surgery, mice received
9mg/Kg bodyweight of Ampi-dry (Dopharma). After 4 weeks, the mice
were euthanized by cervical dislocation and the osteochondral biopsies
were carefully retrieved and fixed in 4% formalin for 1 week. The
specimens were then decalcified with 10% ethylenediaminetetraacetic
acid (EDTA) for 2 weeks and subsequently embedded in paraffin, sec-
tioned and subjected to histological evaluation. Animal experiments
were conducted in the animal facility of the Erasmus MC with approval
of the animal ethics committee (under protocol numbers EMC 3284 and
AVD101002016691).
2.9. Histology and immunohistochemistry
6 μm histological sections of hMSC pellets (sections with the largest
pellet area), FB/HA hydrogels and osteochondral biopsies were stained
with 0.04% thionine solution (Sigma-Aldrich) in demineralized water
to detect glycosaminoglycans (GAGs). Additionally, histological sec-
tions of osteochondral biopsies were subjected to
Fig. 1. Effect of antimiR-221 transfection in hMSCs. (A) hMSCs cultured in monolayer were transfected with different concentrations of antimiR-221 alone or with
lipofectamine (lipo). After 72 h, miR-221 silencing was determined by qRT-PCR. Data are presented as mean ± SD. (B) To test the stability of the inhibitor, antimiR-
221 was pre-incubated at 37 °C for 14 days prior to hMSC transfection. After 72 h, miR-221 silencing was determined by qRT-PCR. Data are presented as mean ± SD.
(C) Ingenuity Pathway Analysis (IPA) performed on RNA-seq data identified upstream regulators associated with the changes in gene expression induced by miR-221
silencing 24 h post-transfection. The activation z-score depicts the degree of activation or suppression of a given factor. (D) To evaluate the effect on chondrogenesis,
hMSCs were transfected with 25 nM antimiR-221 with lipofectamine and cultured as 3D pellets in chondrogenic medium for 28 days. The mRNA expression of
chondrogenesis-related genes was determined by qRT-PCR using HPRT as housekeeping gene. Data are presented as mean ± SD. GAG production and pellet size was
evidenced by thionine staining on sections corresponding to the middle of the pellets.
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immunohistochemistry for collagen type II. After deparaffinization and
rehydration, the sections were enzymatically treated with 1mg/mL
pronase (Sigma-Aldrich) in PBS 1×, followed by treatment with 10mg/
mL hyaluronidase (Sigma-Aldrich) in PBS 1× for antigen retrieval. A
primary antibody against collagen type II (mouse anti-human, 1:100
dilution, II-II/II6B3; Developmental Studies Hybridoma Bank) was pre-
incubated overnight with a biotin-SP F(ab)2-labelled goat anti-mouse
antibody (#115-066-062;Jackson ImmunoResearch Europe) to prevent
cross-reaction with mouse antigens; excessive primary antibody was
captured by addition of 0.1% normal mouse serum prior to the over-
night incubation at 4 °C with the sections. The slides were incubated
overnight with the pre-coupled antibodies at 4 °C. Next, an alkaline
phosphatase-labelled antibody was used (HK-321-UK, Biogenex
Laboratories, CA, USA), which in combination with the Neu Fuchsine
substrate resulted in a red staining. An isotype IgG1 monoclonal anti-
body was used as negative control. Following counterstaining with
haematoxilin, the sections were mounted in VectaMount™ AQ
mounting medium (Vector Labs, CA, USA). For the quantification of in
vivo cartilage repair in the osteochondral defect model, thionine posi-
tivity in the area of the defect was quantified by a computerised video
camera-based image analysis system (NIH, USA ImageJ software, public
domain available at: http://rsb.info.nih.gov/nih-image/) under
brightfield microscopy (two replicates per construct). Cartilage repair
was expressed as % of thionine-positive area.
2.10. Statistical analysis
For the quantification of cartilage repair in the osteochondral
samples, statistically significant differences were determined with IBM
SPSS Statistics using a linear mixed model. Differences were considered
statistically significant for p-values≤ .05.
3. Results
3.1. Transfection of antimiR-221 into hMSCs leads to inhibition of miR-221
function and stimulation of chondrogenesis
We first aimed to demonstrate that antimiR-221 could be effectively
delivered to hMSCs and block miR-221 function. Since LNA oligonu-
cleotides were previously shown to undergo spontaneous internaliza-
tion by the cells [23], we performed transfection both in the presence
and absence of lipofectamine as a carrier. Transfection of antimiR-221
into hMSCs cultured in monolayer led to effective silencing of miR-221
after 72 h, for concentrations of antimiR-221 in the range 5-50 nM
Table 1
RNA-seq analysis of differential gene expression in hMSCs transfected with antimiR-221. hMSCs cultured in monolayer were transfected with antimiR-221 or
antimiR-Scr for 24 h, prior to RNA isolation and RNA-seq analysis. The 43 genes found to be significantly modulated by antimiR-221 transfection (adjusted p-value
(padj)≤ 0.05) are reported in the table. TGF-β related genes are highlighted in bold.
Gene ID Gene description Gene symbol Fold change padj Predicted(P)/validated(V)
hsa-miR-221-3p target
ENSG00000119280 Chromosome 1 open reading frame 198 C1orf198 1.8493 3.38E-12
ENSG00000122376 Shieldin complex subunit 2 SHLD2 2.0606 8.99E-12
ENSG00000081087 Osteoclastogenesis associated transmembrane protein 1 OSTM1 1.8402 9.56E-10 P
ENSG00000137801 Thrombospondin 1 THBS1 1.4707 2.93E-07 V [41]
ENSG00000118523 Cellular communication network factor 2 CCN2 (CTGF) 1.5998 9.12E-07
ENSG00000112096 Superoxide dismutase 2 SOD2 1.5492 1.37E-06 P
ENSG00000149428 Hypoxia up-regulated 1 HYOU1 1.4522 1.78E-06
ENSG00000119314 Polypyrimidine tract binding protein 3 PTBP3 1.5146 3.93E-06 P
ENSG00000117054 Acyl-CoA dehydrogenase medium chain ACADM 1.5483 6.82E-06 P
ENSG00000142871 Cellular communication network factor 1 CCN1 (CYR61) 1.5121 1.78E-05
ENSG00000072506 Hydroxysteroid 17-beta dehydrogenase 10 HSD17B10 1.5360 7.22E-05
ENSG00000148677 Ankyrin repeat domain 1 ANKRD1 1.7293 5.32E-04
ENSG00000197965 Myelin protein zero like 1 MPZL1 1.3792 6.52E-04 P
ENSG00000006652 Interferon related developmental regulator 1 IFRD1 1.5774 6.87E-04 P
ENSG00000176871 WD repeat and SOCS box containing 2 WSB2 1.3780 6.87E-04 P
ENSG00000136888 ATPase H+ transporting V1 subunit G1 ATP6V1G1 1.3540 1.69E-03
ENSG00000165617 Dishevelled binding antagonist of beta catenin 1 DACT1 1.5220 2.41E-03
ENSG00000106484 Mesoderm specific transcript MEST 1.3437 2.45E-03
ENSG00000135048 Cell migration inducing hyaluronidase 2 CEMIP2 1.4289 2.63E-03
ENSG00000106366 Serpin family E member 1 SERPINE1 1.3737 3.06E-03
ENSG00000133816 Microtubule associated monooxygenase, calponin and LIM domain containing 2 MICAL2 1.3194 4.89E-03
ENSG00000168610 Signal transducer and activator of transcription 3 STAT3 1.3180 4.89E-03
ENSG00000134954 ETS proto-oncogene 1, transcription factor ETS1 1.3651 6.16E-03 V [42]
ENSG00000075568 Transmembrane protein 131 TMEM131 0.6939 6.18E-03
ENSG00000125445 Mitochondrial ribosomal protein S7 MRPS7 1.3967 6.71E-03 P
ENSG00000033867 Solute carrier family 4 member 7 SLC4A7 1.3889 7.46E-03 P
ENSG00000178904 dpy-19 like C-mannosyltransferase 3 DPY19L3 1.4131 8.44E-03
ENSG00000101224 Cell division cycle 25B CDC25B 0.7231 9.80E-03
ENSG00000082482 Potassium two pore domain channel subfamily K member 2 KCNK2 1.3322 1.04E-02 P
ENSG00000168374 ADP ribosylation factor 4 ARF4 1.2939 1.07E-02 V [43]
ENSG00000114850 Signal sequence receptor subunit 3 SSR3 1.2874 1.10E-02
ENSG00000117862 Thioredoxin domain containing 12 TXNDC12 1.3584 1.60E-02
ENSG00000221852 Keratin associated protein 1–5 KRTAP1-5 1.3728 1.69E-02
ENSG00000104852 Small nuclear ribonucleoprotein U1 subunit 70 SNRNP70 0.7612 1.96E-02
ENSG00000128342 LIF, interleukin 6 family cytokine LIF 1.5151 2.15E-02
ENSG00000170961 Hyaluronan synthase 2 HAS2 1.3339 2.26E-02
ENSG00000135905 Dedicator of cytokinesis 10 DOCK10 1.3366 2.27E-02
ENSG00000166224 Sphingosine-1-phosphate lyase 1 SGPL1 1.3507 2.58E-02
ENSG00000104738 Minichromosome maintenance complex component 4 MCM4 0.7134 3.60E-02
ENSG00000073712 Fermitin family member 2 FERMT2 1.3192 3.95E-02 P
ENSG00000196205 Eukaryotic translation elongation factor 1 alpha 1 pseudogene 5 EEF1A1P5 1.4437 3.96E-02
ENSG00000099194 Stearoyl-CoA desaturase SCD 1.2899 4.96E-02 P
ENSG00000143183 Transmembrane and coiled-coil domains 1 TMCO1 1.2778 4.99E-02
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(Fig. 1A). In the presence of lipofectamine we achieved a strong miR-
221 knockdown (>99% silencing) for concentrations of antimiR-
221≥25 nM, while a higher dose was required in the case of unassisted
transfection (50 nM; Fig. 1A).
Next, to assess the stability of the inhibitor we pre-incubated
antimiR-221 in PBS at 37 °C for 14 days, prior to transfection of hMSCs
cultured in monolayer. We observed effective miR-221 silencing both in
the presence and absence of lipofectamine, suggesting that antimiR-221
remains functional over time (Fig. 1B).
To further investigate the effect of miR-221 silencing in hMSCs, we
performed RNA-seq analysis on cells transfected with antimiR-221 for
24 h. We identified 43 significantly modulated genes (Table 1). To
determine whether the observed changes in gene expression could be
attributed to the modulation of specific upstream regulators, an In-
genuity Pathway Analysis (IPA) was performed using the significantly
modulated genes as inputs. “hsa-miR-221-3p” was identified as up-
stream regulator with the highest z-score of inhibition (Fig. 1C). Fur-
thermore, a cross-reference analysis with microRNA target databases
identified 15 upregulated genes in the dataset as putative or experi-
mentally validated targets of miR-221 (Table 1). These data show that
transfection of antimiR-221 into hMSCs led to inhibition of miR-221
expression and function, with de-repression of known miR-221 target
genes.
We previously demonstrated that miR-221 silencing has a pro-
chondrogenic effect in hMSCs [21]. Interestingly, the IPA analysis in-
dicated “TGF-β1” as upstream regulator with the highest z-score of
activation (Fig. 1C), and 14 TGF-β related genes were found to be
significantly modulated by miR-221 silencing (Table 1, genes in bold).
When hMSCs transfected with antimiR-221 were cultured as 3D pellets,
miR-221 silencing led to increased mRNA expression of collagen II but
not of collagen X, in addition to increased aggrecan mRNA expression
in a donor-dependent manner (Fig. 1D). Thionine staining evidenced
enhanced GAG production in hMSCs transfected with antimiR-221
(Fig. 1D).
Altogether, our data indicate that transfection of antimiR-221 into
hMSCs effectively blocks miR-221 function and enhances their chon-
drogenic potential.
3.2. FB/HA hydrogels enable effective cell transfection and knockdown of
miR-221 in situ
We aimed to develop a hydrogel-based system for delivering
antimiR-221 to endogenous cells and inducing miR-221 knockdown in
situ. We selected a FB/HA conjugate hydrogel that is particularly pro-
mising for cartilage repair applications in vivo [22,26], and already
clinically approved as a medical device (Regenogel™) for the local
treatment of osteoarthritis.
We first investigated whether FB/HA provided a favourable en-
vironment for cell transfection with antimiR-221. FB/HA hydrogels
were loaded with antimiR-221/lipofectamine and hMSCs immediately
prior to polymerization induced by thrombin, and the hydrogels were
cultured in vitro for 7 days. qRT-PCR analysis demonstrated effective
miR-221 knockdown, with a dose-dependent effect for concentrations
of antimiR-221 in the range 25–250 nM (Fig. 2A).
Flow cytometry analysis showed that a high percentage of cells were
transfected with antimiR-221 already after 3 days of culture in FB/HA
loaded with antimiR-221 (~80% for 50 nM antimiR-221; Fig. 2B).
Importantly, cell viability in the hydrogels was not affected by the
presence of antimiR-221 or lipofectamine up to 14 days of culture (Fig.
S1). Thus, FB/HA provides a supportive environment for cell transfec-
tion with antimiR-221.
To determine whether FB/HA could potentially retain antimiR-221
when applied in an osteochondral defect to transduce cells that invade
the matrix over time, we next assessed the release profile of the in-
hibitor from the hydrogel. As shown in Fig. 3A, FB/HA retained most of
the antimiR-221/lipofectamine complexes over 14 days of in vitro cul-
ture. Dissolution of the hydrogels at day 14 confirmed that> 85% of
the antimiR-221 was still present in the gel (Fig. 3B). When FB/HA was
loaded with antimiR-221 without lipofectamine carrier, the release of
the inhibitor was faster (Fig. 3A). Nevertheless, ~50% of the inhibitor
was still retained by FB/HA after 14 days (Fig. 3B). These data indicate
that FB/HA retains antimiR-221 over time, with or without a carrier,
and provides a supportive environment for hMSC transfection. Inter-
estingly, these findings were not unique for FB/HA, as comparable re-
sults were obtained when a collagen I hydrogel was used (Fig. S2).
Next, in order to mimic the process of transfection of endogenous
cells that migrate into a hydrogel, hMSCs were seeded on the surface of
FB/HA hydrogels loaded with antimiR-221 with or without lipofecta-
mine, and allowed to infiltrate the constructs. As shown in Fig. 3C, qRT-
PCR analysis performed after 7 days of culture demonstrated effective
inhibition of miR-221. While miR-221 knockdown was particularly
strong in the presence of lipofectamine (> 99%), even in the case of
unassisted transfection a silencing efficiency of 60% to 80% was
achieved for concentrations of antimiR-221 in the range 50-250 nM.
Loading of FB/HA with a scrambled antimiR molecule had no effect on
miR-221 levels, confirming that inhibition of miR-221 by antimiR-221
was specific (Fig. 3C).
Finally, we assessed antimiR-221 stability in the hydrogels by pre-
culturing FB/HA loaded with 250 nM antimiR-221 for 14 days at 37 °C
prior to hMSC seeding. The constructs were still capable of inducing
Fig. 2. FB/HA conjugate hydrogel supports transfection of antimiR-221 into hMSCs. (A) hMSCs were cultured in FB/HA hydrogels loaded with different con-
centrations of antimiR-221 with lipofectamine. miR-221 silencing was determined by qRT-PCR at day 7 and data are presented as mean ± SD. (B) hMSCs were
cultured in FB/HA hydrogels loaded with 50 nM FAM-labelled antimiR-221 with lipofectamine. After 3 days, hMSCs were retrieved and analyzed by flow cytometry
to quantify the transfection efficiency (2D = monolayer positive control). Data are presented as mean ± SD.
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miR-221 silencing, confirming that antimiR-221 retained by FB/HA
remains functional for a period of at least 2–3weeks (Fig. 3D). A
comparison between pre-cultured and freshly prepared hydrogels
(Fig. 3D and C, respectively) indicated no difference in miR-221 si-
lencing for lipofectamine-assisted transfection (from 99.7% to 98.5%),
and a small decrease for unassisted transfection (from 84.3% to 64.1%),
likely due to the faster release of the inhibitor.
Taken together, our data show that FB/HA hydrogel loaded with
antimiR-221 represents a suitable delivery system for the transfection of
endogenous cells. While carrier-assisted transfection enhanced the po-
tency of the system, even in the absence of a carrier FB/HA hydrogels
retained antimiR-221 overtime and induced miR-221 silencing in
hMSCs in situ.
3.3. FB/HA hydrogels loaded with antimiR-221/lipofectamine enhance
endogenous cartilage repair in vivo
To assess the effect of antimiR-221 delivery by FB/HA on en-
dogenous joint-resident cells, we employed an in vivo model that si-
mulates an osteochondral defect [21,27]. While we previously in-
vestigated the chondrogenic potential of in vitro cultured cells loaded in
different hydrogels, we now exploited the osteochondral model to re-
capitulate the endogenous cartilage repair process.
We first confirmed that FB/HA supported chondrogenesis of pro-
genitor cells by embedding bone marrow-derived hMSCs in the hy-
drogel and culturing in chondrogenic medium in vitro (Fig. S3A). Next,
osteochondral defects were created in bovine osteochondral biopsies
and filled with FB/HA only (control) or FB/HA loaded with 0.04 μg
antimiR-221 (250 nM concentration) with or without lipofectamine
(Fig. 4A). Since unassisted transfection proved overall less effective in
vitro, a higher dose of 0.4 μg antimiR-221 without lipofectamine was
also included. Defects not filled with the hydrogel (empty) were
included as negative control condition (Fig. S3B). The constructs were
implanted subcutaneously in nude mice and retrieved after 4 weeks to
evaluate the potency of the system to induce cartilage repair. As shown
in Fig. 4B, all hydrogel conditions proved favourable for the invasion of
endogenous cells, their differentiation into chondrocytes, and the pro-
duction of repair cartilage within the osteochondral defects. However,
we observed some variability in endogenous cell infiltration, with
~20% of the specimens showing limited cell invasion (an example is
shown in Fig. S3C).
To determine whether delivery of antimiR-221 to endogenous cells
improved cartilage repair, we quantified the thionine-positive area in
the osteochondral defects (Fig. 4C). Since our approach of in situ
transfection of endogenous cells relies on good cellular invasion, we
excluded from the analysis the specimens with limited cell infiltration
(shown as grey circles in Fig. 4C). In the case of unassisted transfection,
the lower antimiR-221 dose led to a slight increase in the amount of
repair cartilage, that did not reach statistical significance. Only 2 of the
5 specimens showed increased cartilage production in comparison to
control hydrogels, suggesting a certain degree of variability in the ef-
ficacy of in vivo unassisted transfection. When lipofectamine was used
as a carrier, loading of FB/HA with antimiR-221 enhanced cartilage
repair by endogenous cells, with a significant 2-fold increase in the
amount of repair cartilage (Fig. 4B–C).
Immunohistochemical analysis of the constructs evidenced abun-
dant production of the hyaline cartilage marker collagen II within the
newly-formed tissue, particularly in the case of FB/HA loaded with
antimiR-221/lipofectamine (Fig. 4B).
In conclusion, our data demonstrate that delivery of antimiR-221 to
endogenous cells by a suitable hydrogel material significantly enhanced
cartilage repair by endogenous cells in vivo. The effect was particularly
evident in the presence of lipofectamine as a carrier, that likely in-
creased the effectiveness of in vivo transfection.
Fig. 3. Validation of antimiR-221 loaded FB/HA as delivery system for cell transfection in situ. (A) FB/HA hydrogels were loaded with FAM-labelled antimiR-221
alone or with lipofectamine. The cumulative release of antimiR-221 was determined by measuring the concentration of antimiR-221 in the releasates. (B) The
histogram depicts the % of antimiR-221 release and retention at the end-point (day 14). Data are presented as mean ± SD. (C) hMSCs were seeded on the surface of
FB/HA hydrogels loaded with different concentrations of antimiR-221 or antimiR-Scr alone or with lipofectamine, and allowed to infiltrate the constructs. After
7 days, miR-221 silencing was determined by qRT-PCR. Data are presented as mean ± SD. (D) FB/HA hydrogels loaded with antimiR-221 or antimiR-Scr alone or
with lipofectamine were pre-incubated at 37 °C for 14 days, prior to hMSC seeding on the surface of the hydrogels. miR-221 silencing was determined by qRT-PCR
7 days post-seeding. Data are presented as mean ± SD.
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4. Discussion
In this study, we demonstrated that implantation of an
antimicroRNA-loaded hydrogel in osteochondral defects significantly
enhanced cartilage production by endogenous cells. miR-221 was se-
lected as candidate microRNA based on our previous studies [20,21],
and was here validated as a potential target to guide endogenous car-
tilage repair in vivo. To the best of our knowledge, our findings provide
first indication that hydrogel-assisted antimicroRNA delivery may serve
as a novel approach to stimulate endogenous cartilage repair.
Our work strongly supports the idea of targeting anti-chondrogenic
factors to guide cartilage repair. The research on novel strategies for
cartilage repair has so far focused almost exclusively on the stimulation
of cartilage anabolism, especially via growth factor therapy. Despite the
hype surrounding such preparations, their effectiveness is still debated
and a lack of standardization is limiting their clinical use [28,29]. In-
terestingly, endogenous anabolic stimuli in the joint may be already
sufficient for cartilage repair, as indicated by the spontaneous forma-
tion of cartilaginous tissue following microfracture. However, the fact
that cartilage repair is often impaired by insufficient production or
degeneration of the repair tissue suggests the presence of anti-chon-
drogenic factors in the joint environment that counteract regeneration.
In this regard, a number of anti-chondrogenic regulators, including
microRNAs, have been characterized, and a growing body of evidence
indicates that targeting these factors may “release the brakes” and
create better conditions to achieve optimal cartilage repair (reviewed in
[30,31]). This is further confirmed by the outcome of our study, that
validates miR-221 as target to enhance the chondro-regenerative po-
tential of endogenous cells. While the molecular mechanism supporting
the pro-chondrogenic effect of miR-221 silencing remains to be
Fig. 4. Effect of antimiR-221 loaded FB/HA hydrogels on endogenous cartilage repair in vivo. (A) Osteochondral defects (Ø 4mm) were produced in bovine
osteochondral biopsies and filled with FB/HA hydrogels loaded with the indicated doses of antimiR-221 with or without lipofectamine, performing in situ poly-
merization (L= low dose; H=high dose). The constructs were implanted subcutaneously in nude mice for 4 weeks. (B) Newly-formed cartilage in the osteochondral
defects was evidenced by thionine staining and collagen II production was evidenced by immunohistochemistry. Representative sections are shown. (C) Cartilage
repair was quantified by measuring the % of the osteochondral defects filled with thionine-positive repair cartilage. Data are presented as dot plot with average
values. Statistical significance was determined using a linear mixed model (*p < .05).
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determined, our data suggest that an interplay between miR-221 and
the TGF-β signaling may be implicated.
Our strategy is based on the manipulation of endogenous cells via
non-viral transfection of an antimiR oligonucleotide. Non-viral carriers
are a preferable choice for translational research, being safer and
cheaper [32]. Furthermore, they can serve as a minimally invasive
mean to trigger a regenerative response, while allowing the host tissues
to gradually take over tissue repair. Here we loaded antimiR-221 into a
FB/HA hydrogel, in combination with lipofectamine as state-of-the-art
non-viral carrier, or without carrier to evaluate unassisted transfection.
While lipofectamine-mediated transfection performed better in all ex-
periments, both strategies led to efficient cell transfection and miR-221
silencing in situ. This was likely favored by the existence of an inter-
action between antimiR-221 or lipofectamine and FB/HA, as indicated
by the high retention of functional inhibitor over a period of weeks.
These findings are consistent with recent studies that showed co-loca-
lization of LNA-oligonucleotides and fibrin fibers within different hy-
drogels [33,34]. Interestingly, this approach may also be applied to
different biomaterials, as demonstrated by our results obtained with a
collagen I hydrogel. Further studies are needed to elucidate the exact
nature of the interactions between hydrogels and LNA-oligonucleotides,
since manipulation of the material properties may allow to alter the
release profile as desired. Finally, it will be important to investigate
whether differences in the release profile may arise in vivo due to the
presence of cells and biological fluids.
AntimiR-221 was found to transfect progenitor cells and inhibit
miR-221 expression in vitro both with and without the use of lipo-
fectamine carrier. When antimiR-221 loaded FB/HA hydrogels were
implanted in an osteochondral defect model, however, only carrier-
assisted transfection led to a significant increase in endogenous carti-
lage repair. We hypothesize that a lower antimiR-221 retention and
transfection efficiency in the absence of the carrier made it challenging
to observe a clear biological effect. The large differences in cartilage
repair observed in these specimens may reflect a high variability in the
effectiveness of in vivo unassisted transfection. Interestingly, increasing
the antimiR-221 dose did not lead to further improvements, suggesting
that a higher local concentration of the inhibitor (at least in the early
phase post-implantation) did not compensate for a reduced transfection
efficiency. These findings provide valuable directions for future work,
that should focus on the optimization of the hydrogel formulation (e.g.
FB/HA ratio and amount of crosslinking) to identify conditions that
may increase antimiR retention and/or transfection efficiency.
Of note, the process of endogenous cartilage repair is only partially
understood and the specific contribution of different progenitor/stem
cell populations has not yet been elucidated. Full-thickness cartilage
lesions induce blood clot formation, invasion of multipotent cells and
fibrocartilage production. In 1993, Shapiro et al. attributed endogenous
cartilage repair to bone marrow cells by radiolabeling [7]. It is now
clear that bone marrow is not the only tissue involved, and various
progenitor cell populations contribute to endogenous cartilage repair,
e.g. cells from synovium and the surface zone of articular cartilage [35].
A recent study demonstrated that the progenitor cells involved in ar-
ticular cartilage repair are predominantly of the GDF5-lineage, and
these cells reside in the synovium, subchondral bone marrow and ar-
ticular cartilage [36]. Unfortunately, an in-depth investigation of the
precise cellular and molecular events still lacks. While this “knowledge
gap” should not discourage the development of tools for endogenous
cartilage repair, it would be of major relevance for establishing targeted
approaches directed towards specific cell populations. Importantly, the
pro-chondrogenic effect of antimiR-221 is not restricted to a specific
progenitor cell source, as indicated by the results obtained with fetal
umbilical cord and adult bone marrow hMSCs [21], as well as ded-
ifferentiated intervertebral disc cells [37]. This versatility likely relates
to the targeting of miR-221 as a crucial anti-chondrogenic regulator
that inhibits chondrogenesis in progenitor cells of various origin. Our
current work further supports this concept and leads us to speculate
that an antimiR-221 based approach could potentially target any source
of chondro-progenitor cells invading the osteochondral defect.
In this work we did not focus on the issue of stimulating the pro-
liferation and recruitment of endogenous cells. The bovine osteochon-
dral model displayed an overall high rate of endogenous cell infiltra-
tion, likely favored by the young age of the animals and the healthy
state of the joint. However, ~20% of the constructs exhibited limited
rate of endogenous cell ingrowth and had to be excluded from the
analysis. It is likely that in the context of an osteochondral lesion, the
rate of endogenous cell invasion is impacted by several factors, in-
cluding patient specific characteristics. To address this need, few stu-
dies have succeeded in loading proliferative and/or chemotactic factors
in scaffolds to enhance the recruitment of endogenous cells to the le-
sion. Collagen I scaffold containing stromal cell-derived factor 1 were
employed to enhance endogenous repair of partial-thickness defects in
rabbits [38]. TGF-β3 and mechano growth factor-functionalized silk
fibroin scaffolds enhanced endogenous cell recruitment and in situ ar-
ticular cartilage regeneration in a rabbit model [39]. In addition to the
use of chemokines, employing materials with properties that are par-
ticularly favourable for endogenous cell infiltration, adhesion and sur-
vival may significantly impact endogenous repair. A number of material
features such as surface chemistry, micro/nanotopography and matrix
stiffness can exert a profound influence on cell behavior [40]. These
parameters should be carefully taken into account and properly mod-
ified to enhance the “cell colonizing properties” of the biomaterial. In
this view, our antimiR-221 based system could be implemented with
chemotactic factors and/or modified biomaterial properties to further
extend its application to situations where endogenous cell infiltration is
expected to be limited.
Our results were obtained using a bovine osteochondral biopsy
model to study cartilage repair in a simulated osteochondral defect in
vivo. Also in consideration of previous work [21,27], this proved as a
valuable strategy to investigate early events involved in cartilage re-
pair, including the attraction of endogenous cells, their differentiation
into chondrocytes and cartilage matrix production. The model also has
limitations, related to its ectopic nature and the absence of proper
mechanical forces. Future development of our approach will require
validation studies in the context of orthotopic osteochondral defects in
large size animals. Importantly, this will allow to investigate the me-
chanical properties and the long-term stability of the repair cartilage
generated by antimiR-221 treatment, and may pave the way for po-
tential applications.
5. Conclusions
In conclusion, this study established a novel non-invasive FB/HA
hydrogel-based approach that exploits antimicroRNA therapy to en-
hance endogenous repair of osteochondral defects. This system is highly
versatile and may be easily adapted for the use of different biomaterials
or for targeting alternative inhibitors of tissue repair. In addition, our
work may contribute to further development of microRNA therapy for
tissues where biomaterial-driven manipulation of microRNAs has
shown significant therapeutic potential, including cartilage, bone, heart
and nervous system. We hope that our findings will give further impulse
to these fields, pushing in the direction of translational research on
microRNA therapy for tissue repair.
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